[{"data":1,"prerenderedAt":14},["ShallowReactive",2],{"blog-grant-intelligence-non-dilutive-funding":3},{"category":4,"content":5,"date":6,"description":7,"faq":8,"ogTitle":9,"readTime":10,"slug":11,"tags":12,"title":9},"Grant Intelligence","\u003Ch2 class=\"text-3xl font-bold mb-6\">The Grant Intelligence Opportunity\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The US federal government awards over $4 billion annually through the Small Business\n              Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The\n              National Institutes of Health (NIH) alone administers more than $1 billion in\n              SBIR\u002FSTTR funding each year, supporting early-stage R&D in medical devices,\n              diagnostics, therapeutics, and digital health.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              For MedTech companies, non-dilutive grant funding offers a pathway to advance product\n              development without surrendering equity. But the grant landscape is vast and\n              fragmented. Funding opportunities span dozens of federal agencies, each with its own\n              priorities, deadlines, and submission requirements. Tracking which opportunities align\n              with a company's technology, understanding the competitive landscape for each grant\n              program, and monitoring competitors' grant activity requires dedicated intelligence\n              capabilities that most MedTech companies lack.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform transforms grant intelligence from a manual, periodic search into a\n              continuous signal monitoring system. By integrating grant data from multiple federal\n              databases and correlating it with regulatory, competitive, and market access signals,\n              the platform gives MedTech companies a complete picture of the funding landscape and\n              how it connects to commercial outcomes.\n            \u003C\u002Fp>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">\n              The Four Domains of Grant-Fueled Intelligence\n            \u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Grant signals are the earliest indicators of MedTech innovation. A company that\n              receives a Phase I SBIR award is at the beginning of a journey that may lead, years\n              later, to FDA clearance and commercial launch. The CI Platform tracks grants as the\n              first domain in a four-domain signal intelligence system, enabling users to see the\n              full arc of innovation from early funding through market success.\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-primary-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Grant and Funding Signals\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  The CI Platform monitors Grants.gov, NIH RePORTER, and other federal funding\n                  databases for new SBIR and STTR awards, Phase I to Phase II transitions, NIH grant\n                  renewals, DoD medical research awards, and other non-dilutive funding events. Each\n                  award is classified by therapeutic area, technology type, award value, and agency.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Users can track funding activity by technology category, competitor company, or\n                  geographic region. The platform surfaces trends such as increasing award values in\n                  a specific therapeutic area, new agency focus areas indicated by solicitations,\n                  and companies that are successfully progressing from Phase I to Phase II and\n                  beyond.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Signal types:\u003C\u002Fstrong> New SBIR\u002FSTTR awards, Phase transitions, NIH grant\n                  renewals, DoD medical research grants, NSF convergence accelerator awards, BARDA\n                  funding opportunities, and state-level innovation grants.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-accent-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">\n                  Regulatory Signals from Grant-Funded Research\n                \u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Grant-funded research often leads to regulatory submissions. A company that\n                  receives an SBIR Phase II award for a novel diagnostic platform is likely to file\n                  a 510(k) submission within 12 to 24 months. The CI Platform correlates grant\n                  awards with subsequent regulatory filings, giving users early visibility into the\n                  pipeline of products heading toward market clearance.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  This correlation is particularly valuable for competitive intelligence. By\n                  tracking which companies are receiving grants in specific technology areas and\n                  monitoring their subsequent regulatory activity, users can anticipate competitive\n                  product launches years before they reach the market. A competitor that has\n                  received multiple grants in a concentrated technology area and has begun filing\n                  patent applications is sending a clear signal about its R&D priorities.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Signal types:\u003C\u002Fstrong> Grant-to-regulatory submission tracking,\n                  grant-funded patent filings, SBIR awardee regulatory clearance rates, technology\n                  area funding-to-market timelines, and competitor R&D pipeline mapping.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-emerald-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Market Access Signals from Grant Winners\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Companies that successfully navigate from grant funding through regulatory\n                  clearance to market access represent the highest-value innovation pipeline. The CI\n                  Platform tracks the complete commercialization journey, from initial SBIR award\n                  through international registration and coverage determination.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Users can benchmark their own progress against peers, identifying how long it\n                  takes companies in their technology area to move from grant award to first\n                  regulatory clearance, and from clearance to first international registration.\n                  These benchmarks inform strategic planning and resource allocation for product\n                  development and market access teams.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Signal types:\u003C\u002Fstrong> Grant-to-market access timing benchmarks,\n                  technology area commercialization rates, international expansion patterns of\n                  grant-funded companies, and acquisition targets identified through grant-to-market\n                  trajectories.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-violet-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Lead Intelligence from Grant Activity\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Grant activity is a powerful lead generation signal. Companies that have received\n                  SBIR awards are actively developing new technologies and may need manufacturing\n                  partners, clinical trial sites, distribution agreements, or additional funding.\n                  The CI Platform transforms grant awards into qualified leads by enriching them\n                  with company profiles, regulatory history, and technology focus.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  A company that transitions from SBIR Phase I to Phase II signals increasing\n                  technology maturity and approaching commercialization. This is an ideal time for\n                  partnership outreach. A company with multiple grants across related technology\n                  areas signals deep expertise and a broad R&D pipeline. The platform surfaces these\n                  opportunities automatically, scoring leads by grant activity density, technology\n                  alignment, and commercialization stage.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Signal types:\u003C\u002Fstrong> Phase transition-based leads, grant-funded company\n                  identification, technology alignment scoring, partnership opportunity detection,\n                  and M&A target identification through grant portfolio analysis.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">\n              Key Grant Programs and Databases Monitored\n            \u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform provides comprehensive coverage of the major federal grant programs\n              that fund MedTech innovation. Here is an overview of the key programs and what their\n              signals reveal.\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">NIH SBIR\u002FSTTR Program\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  The NIH SBIR\u002FSTTR program is the largest source of federal non-dilutive funding\n                  for biomedical innovation, awarding over $1 billion annually across 27 NIH\n                  institutes and centers. Awards are classified by institute (NCI, NHLBI, NIBIB,\n                  etc.), technology area, and award phase. The CI Platform tracks all NIH SBIR\u002FSTTR\n                  awards, including contract and grant mechanisms, and correlates them with\n                  subsequent research outputs and regulatory activity.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">DoD Medical Research Programs\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  The Department of Defense operates multiple medical research programs through the\n                  Defense Health Agency, Army Medical Research and Development Command, and other\n                  entities. DoD medical awards often focus on trauma care, battlefield medicine,\n                  infectious diseases, and rehabilitation technologies. These awards signal\n                  government priority areas and often lead to dual-use technologies with commercial\n                  applications. The CI Platform tracks DoD medical research grants, contracts, and\n                  other funding mechanisms.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">NSF Convergence Accelerator and SBIR\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  The National Science Foundation funds early-stage deep technology development\n                  through its SBIR\u002FSTTR program and Convergence Accelerator. NSF awards focus on\n                  foundational technologies with broad application potential, including AI\u002FML for\n                  healthcare, advanced manufacturing for medical devices, and biosensing platforms.\n                  NSF awardees signal technology readiness for commercial translation. The CI\n                  Platform tracks NSF funding across all relevant technology tracks.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">BARDA and HHS Funding\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  The Biomedical Advanced Research and Development Authority (BARDA) provides\n                  funding for medical countermeasures, diagnostics, and pandemic preparedness\n                  technologies. BARDA awards signal federal prioritization of specific technology\n                  areas and often include pathways to procurement. HHS also administers other\n                  innovation funding programs relevant to MedTech. The CI Platform tracks BARDA\n                  contracts, Other Transaction Authority agreements, and related HHS funding\n                  mechanisms.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Cross-Domain Grant Intelligence\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform's grant intelligence goes beyond award tracking. By correlating grant\n              signals with data from the other three domains, the platform provides strategic\n              context that transforms raw funding data into actionable intelligence.\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-primary-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  1\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Competitive Grant Landscape Analysis\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    See which companies are winning grants in your technology area, how much funding\n                    they have received, and at what phase. Identify emerging competitors before they\n                    reach regulatory submission. Track grant concentration by geography, technology,\n                    and company size.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-accent-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  2\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Grant-to-Regulatory Pipeline Tracking\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Monitor the pipeline of grant-funded technologies approaching regulatory\n                    submission. Companies that have completed SBIR Phase II awards and filed patent\n                    applications are likely to submit 510(k) or PMA applications within 12 to 24\n                    months. Early visibility enables strategic planning for competitive response and\n                    partnership outreach.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-primary-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  3\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Funding Trend Detection\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Identify shifts in federal funding priorities before they are widely announced.\n                    Increasing award concentrations in specific technology areas signal growing\n                    agency interest. Decreasing award values in other areas may signal shifting\n                    priorities. The platform surfaces these trends through automated analysis of\n                    award patterns across agencies and time periods.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-accent-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  4\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Lead Generation from Grant Activity\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Grant-funded companies at specific commercialization stages are ideal targets\n                    for partnership, investment, or acquisition. The platform scores these leads by\n                    technology alignment, commercialization stage, and signal density, enabling\n                    targeted outreach to the most relevant opportunities.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">\n              How the CI Platform Delivers Grant Intelligence\n            \u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform is purpose-built for cross-domain signal intelligence, with specific\n              capabilities for grant monitoring and analysis.\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Continuous Grant Monitoring\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Automated systems monitor Grants.gov, NIH RePORTER, DoD funding databases, and\n                  other sources around the clock. New awards, solicitations, and funding updates are\n                  ingested and classified within hours of publication.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Entity Resolution and Company Linking\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Every grant award is linked to its recipient company through entity resolution,\n                  building a complete funding history for each company. Users can see the total\n                  grant funding a company has received, across which agencies, and for which\n                  technology areas.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Cross-Domain Correlation\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Grant awards are automatically correlated with regulatory filings, patent grants,\n                  clinical trial registrations, and funding events. Each company's complete\n                  innovation timeline, from first grant award through market entry, is visible in a\n                  single view.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Custom Alerting and Opportunity Delivery\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Users configure alerts for grant opportunities matching their technology area,\n                  competitive grant awards in their space, and funding trend changes in their target\n                  markets. Each alert is enriched with the full company and technology context for\n                  immediate action.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Why Grant Intelligence Matters Now\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Federal funding for MedTech innovation is at historic levels, driven by pandemic\n              preparedness priorities, cancer moonshot initiatives, and advanced research projects\n              agency funding. The NIH budget has grown steadily, with increased emphasis on\n              translational research and commercialization. The SBIR\u002FSTTR programs continue to\n              expand their focus areas and award sizes.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              At the same time, competition for grant funding is intensifying. SBIR\u002FSTTR success\n              rates at NIH have declined as application volumes have increased. Companies that can\n              identify the most favorable funding opportunities, understand agency priorities, and\n              track competitive activity have a significant advantage in securing non-dilutive\n              capital.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-8 leading-relaxed\">\n              The CI Platform gives grant intelligence teams the tools they need to navigate this\n              competitive landscape. By transforming grant data from a static database into a\n              continuous signal monitoring system, correlated with regulatory, competitive, and\n              market intelligence, the platform enables companies to identify opportunities earlier,\n              track competitors more effectively, and connect funding to commercial outcomes.\n            \u003C\u002Fp>","2026-01-01","How the CI Platform transforms grant intelligence into continuous signal monitoring, helping MedTech companies identify SBIR\u002FSTTR opportunities, track competitors, and connect funding to commercialization.",null,"Grant Intelligence: Tracking Non-Dilutive Funding Opportunities with Signal Intelligence",8,"grant-intelligence-non-dilutive-funding",[13],"grant-intelligence",1786979507458]